Gentium S.p.A. (NASDAQ: GENT), a biopharmaceutical company, specializes in discovering, researching, developing and manufacturing active ingredients derived from natural sources as potential therapeutic agents. The company focuses on developing relationships with industrial and academic institutions and intends to discover further beneficial effects of its products as well as develop pharmaceuticals with a broader range of treatment indications. For further information, visit the Company’s web site at http://www.gentium.com.
- 17 years ago
QualityStocks
Gentium S.p.A. (NASDAQ: GENT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – DitGold (CRYPTO: DITAU) Gains Exposure as Coinbase Global Inc. (NASDAQ: COIN) Expands DEX Trading Access
DitGold (CRYPTO: DITAU) is now accessible through the Coinbase app decentralized exchange (DEX) functionality, enabling users to…
-
QualityStocksNewsBreaks – Co-Diagnostics, Inc. (NASDAQ: CODX) Expands CoSara Distribution Territory Across South Asia
Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand…
-
QualityStocksNewsBreaks – Brazil Potash Corp. (NYSE-American: GRO) CEO To Speak At IDB Annual Meeting On Global Food Security
Brazil Potash (NYSE-American: GRO) announced that CEO Matt Simpson has been invited to participate as…